Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380611 | 0.89 | GAA (0.68) | SMN1; SMN2TDP1KDM4EGAAHPGD | |
| SCHEMBL487964 | 0.86 | CD274 (0.84) | SMN1; SMN2KDM4EHPGDCD274KMT2A | |
| SCHEMBL16462027 | 0.82 | CD274 (0.76) | SMN1; SMN2KDM4EHPGDCD274KMT2A | |
| SCHEMBL8167646 | 0.79 | CD274 (1.00) | SMN1; SMN2KDM4EHPGDCD274ALDH1A1 | |
| SCHEMBL15328470 | 0.79 | ALDH1A1 (0.78) | SMN1; SMN2KDM4EGAALMNAKMT2A | |
| SCHEMBL1382764 | 0.79 | SMN1; SMN2 (0.95) | SMN1; SMN2KDM4EGAAHPGDCD274 | |
| SCHEMBL5451782 | 0.79 | GAA (0.90) | SMN1; SMN2KDM4EGAALMNAHTT | |
| SCHEMBL12049629 | 0.77 | KMT2A (1.00) | SMN1; SMN2KDM4EGAALMNAHTT | |
| SCHEMBL4015612 | 0.77 | EPHX2 (0.82) | SMN1; SMN2KDM4EGAAHPGDCD274 | |
| SCHEMBL14096488 | 0.77 | MAPT (0.62) | SMN1; SMN2KDM4EGAAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814366-B2 | Antiviral compounds and use thereof | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2023-11-14 | — | — | US | disclosed |
| EP-3765454-B1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIV DEGLI STUDI DI SIENA (IT) | 2023-11-08 | — | — | EP | disclosed |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITA DEGLE STUDI DI SIENA (IT) | 2021-03-11 | — | — | US | disclosed |
| US-5378706-A | Memory disorders, senile dememtia | SANOFI (FR) | 1995-01-03 | — | — | US | disclosed |
| US-5232921-A | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions | SANOFI (FR) | 1993-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814366-B2 | Antiviral compounds and use thereof | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 2276/4885TDP1 1418/4885KDM4E 2361/4885 |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 2276/4885TDP1 1418/4885KDM4E 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.